image
Healthcare - Medical - Devices - NYSE - US
$ 263.49
0.461 %
$ 10.1 B
Market Cap
712.14
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one PEN stock under the worst case scenario is HIDDEN Compared to the current market price of 263 USD, Penumbra, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one PEN stock under the base case scenario is HIDDEN Compared to the current market price of 263 USD, Penumbra, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one PEN stock under the best case scenario is HIDDEN Compared to the current market price of 263 USD, Penumbra, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart PEN

image
$320.0$320.0$300.0$300.0$280.0$280.0$260.0$260.0$240.0$240.0$220.0$220.0$200.0$200.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
1.19 B REVENUE
12.86%
9.28 M OPERATING INCOME
-87.38%
14 M NET INCOME
-84.59%
168 M OPERATING CASH FLOW
73.10%
77.6 M INVESTING CASH FLOW
582.86%
-87 M FINANCING CASH FLOW
-536.97%
316 M REVENUE
4.81%
42.8 M OPERATING INCOME
20.96%
33.7 M NET INCOME
14.08%
51.1 M OPERATING CASH FLOW
-9.49%
-11 M INVESTING CASH FLOW
-30.67%
6.07 M FINANCING CASH FLOW
106.03%
Balance Sheet Penumbra, Inc.
image
Current Assets 951 M
Cash & Short-Term Investments 340 M
Receivables 168 M
Other Current Assets 443 M
Non-Current Assets 582 M
Long-Term Investments 0
PP&E 268 M
Other Non-Current Assets 314 M
22.18 %10.94 %28.92 %17.51 %20.45 %Total Assets$1.5b
Current Liabilities 158 M
Accounts Payable 31.3 M
Short-Term Debt 14.6 M
Other Current Liabilities 112 M
Non-Current Liabilities 224 M
Long-Term Debt 209 M
Other Non-Current Liabilities 15.1 M
8.20 %3.82 %29.41 %54.62 %3.95 %Total Liabilities$382.3m
EFFICIENCY
Earnings Waterfall Penumbra, Inc.
image
Revenue 1.19 B
Cost Of Revenue 440 M
Gross Profit 755 M
Operating Expenses 746 M
Operating Income 9.28 M
Other Expenses -4.73 M
Net Income 14 M
1b1b1b1b800m800m600m600m400m400m200m200m001b(440m)755m(746m)9m5m14mRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
63.20% GROSS MARGIN
63.20%
0.78% OPERATING MARGIN
0.78%
1.17% NET MARGIN
1.17%
1.22% ROE
1.22%
0.91% ROA
0.91%
0.45% ROIC
0.45%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Penumbra, Inc.
image
150m150m100m100m50m50m00(50m)(50m)(100m)(100m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 14 M
Depreciation & Amortization 23.7 M
Capital Expenditures -21.2 M
Stock-Based Compensation 46.2 M
Change in Working Capital 0
Others 101 M
Free Cash Flow 147 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Penumbra, Inc.
image
Wall Street analysts predict an average 1-year price target for PEN of $222 , with forecasts ranging from a low of $150 to a high of $275 .
PEN Lowest Price Target Wall Street Target
150 USD -43.07%
PEN Average Price Target Wall Street Target
222 USD -15.84%
PEN Highest Price Target Wall Street Target
275 USD 4.37%
Price
Max Price Target
Min Price Target
Average Price Target
320320300300280280260260240240220220200200180180160160140140May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 11
6. Ownership
Insider Ownership Penumbra, Inc.
image
Sold
0-3 MONTHS
32.2 M USD 8
3-6 MONTHS
11.2 M USD 5
6-9 MONTHS
12.7 M USD 4
9-12 MONTHS
3.39 M USD 3
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Penumbra, Inc. Schedules First Quarter 2025 Earnings Release and Conference Call for April 23, 2025 ALAMEDA, Calif. , April 3, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the first quarter 2025 after market close on Wednesday, April 23, 2025 at 4:30 PM Eastern Time. prnewswire.com - 1 week ago
Seven New Data Sets Demonstrate Penumbra's Computer Assisted Vacuum Thrombectomy (CAVT) Technology Is Safe, Fast and Effective, Improves Patient Outcomes, and Delivers Healthcare Resource Benefits ALAMEDA, Calif. , April 2, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced seven significant computer assisted vacuum thrombectomy (CAVT™) data presentations during the 2025 Society of Interventional Radiology (SIR) Annual Scientific Meeting. prnewswire.com - 2 weeks ago
New Thrombectomy Product Launches Support PEN Stock Amid Macro Issues Penumbra expects to materially increase both revenues and profitability in the company's international business in the next few years. zacks.com - 3 weeks ago
Growing Thrombectomy Business Supports PEN Stock, Macro Issues Ail Penumbra is still in the early stages of its journey to bring the company's proprietary thrombectomy technologies to patients in the United States and around internationally. zacks.com - 1 month ago
Penumbra, Inc. Announces Don Kassing will Retire from Board of Directors ALAMEDA, Calif. , Feb. 21, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced today that after 17 years of distinguished service, Don Kassing has notified the company that he will retire from the board of directors effective April 1, 2025. prnewswire.com - 1 month ago
Penumbra (PEN) Upgraded to Buy: Here's Why Penumbra (PEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). zacks.com - 1 month ago
Penumbra Q4 Earnings & Revenues Top, Margins Expand, Stock Rises Penumbra reports better-than-expected earnings and revenues in the fourth quarter of 2024. zacks.com - 1 month ago
Penumbra, Inc. (PEN) Q4 2024 Earnings Call Transcript Penumbra, Inc. (NYSE:PEN ) Q4 2024 Earnings Conference Call February 18, 2025 4:30 PM ET Company Participants Cecilia Furlong - Director of Business Development and Investor Relations Adam Elsesser - Chairman & Chief Executive Officer Maggie Yuen - Chief Financial Officer Jason Mills - Executive Vice President of Strategy Conference Call Participants Larry Biegelsen - Wells Fargo Securities Robert Marcus - JPMorgan Pito Chickering - Deutsche Bank Bill Plovanic - Canaccord Richard Newitter - Truist Securities Samantha Kurtz - Piper Sandler Michael Sarcone - Jefferies Ryan Zimmerman - BTIG Shagun Singh - RBC Capital Markets Michael Kratky - Leerink Partners Operator Good afternoon. My name is Rob and I will be your conference operator today. seekingalpha.com - 1 month ago
Here's What Key Metrics Tell Us About Penumbra (PEN) Q4 Earnings The headline numbers for Penumbra (PEN) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. zacks.com - 1 month ago
Penumbra (PEN) Beats Q4 Earnings and Revenue Estimates Penumbra (PEN) came out with quarterly earnings of $0.97 per share, beating the Zacks Consensus Estimate of $0.91 per share. This compares to earnings of $0.76 per share a year ago. zacks.com - 1 month ago
Penumbra, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results ALAMEDA, Calif. , Feb. 18, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the fourth quarter and full year ended December 31, 2024. prnewswire.com - 1 month ago
Should You Add Penumbra Stock to Your Portfolio Right Now? PEN continues to attract investor interest with its strong portfolio expansion and global expansion efforts. zacks.com - 2 months ago
8. Profile Summary

Penumbra, Inc. PEN

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 10.1 B
Dividend Yield 0.00%
Description Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra RED, JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, BMX96, DDC, and PX SLIM brands. It also provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; aspiration-based thrombectomy systems for vascular applications under the Indigo System brand; and detachable embolic coil systems for peripheral embolization under the Ruby Coil and Ruby LP brand names. In addition, the company offers microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand; and detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand, as well as immersive computer-based technologies and immersive therapeutics to promote health, motor function, and cognition under the Real Immersive System brand; and a complementary device for use with Ruby Coil and POD for vessel occlusion under the Packing Coil and Packing Coil LP brands. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.
Contact One Penumbra Place, Alameda, CA, 94502 https://www.penumbrainc.com
IPO Date Sept. 18, 2015
Employees 4500
Officers Ms. Jee Hamlyn-Harris Investor Relations Officer Mr. Lambert Shiu Chief Accounting Officer Mr. Pankaj Tiwari Executive Vice President & Chief Information Officer Ms. Shruthi Narayan President of Interventional Mr. Ben Tompkins Executive Vice President of Development & Compliance Ms. Maggie S. Yuen Chief Financial Officer Mr. Ben Sorci Executive Vice President of Operations Ms. Johanna Roberts J.D. Executive Vice President, General Counsel & Secretary Dr. Arani Bose M.D. Co-Founder & Director Mr. Adam Elsesser J.D. Co-Founder, Chairman, President & Chief Executive Officer